FDA spurns Minerva’s schizophrenia drug in RTF, sending share price into tailspin
The writing was on the wall.
The FDA spelled out its qualms with Minerva Neurosciences’ schizophrenia drug candidate roluperidone in 2020. Nevertheless, the biotech pushed forward and had meetings with the regulator to attempt to assuage concerns and get its drug to market.
So the biotech went ahead and, in August, asked the drug regulator to approve the treatment for negative symptoms in people with schizophrenia.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.